Trademark: 97072078
Word
NUGALVIQ
Status Date
Friday, March 22, 2024
Filing Date
Wednesday, October 13, 2021
Published for Opposition
Tuesday, August 23, 2022
5 Pharmaceutical preparations for treatment of rare orphan diseases; Pharmaceutical preparations for treatment of diseases that impact sugar and glucose metabolism; Pharmaceutical preparations for inhibiting aldose reductase; Pharmaceutical preparations for treatment of galactosemia, sorbitol dehydrogenase (SORD) deficiency and PMM2-congenital disorder of glycosylation (PMM2-CDG)
The mark consists of three curved vertical lines consisting of dots of graduated sizes, with the word "NUGALVIQ" to the right of the design.
Mar 23, 2024
Notice Of Approval Of Extension Request E-Mailed
Mar 22, 2024
Sou Extension 3 Granted
Mar 22, 2024
Sou Extension 3 Filed
Mar 22, 2024
Sou Teas Extension Received
Sep 21, 2023
Notice Of Approval Of Extension Request E-Mailed
Sep 19, 2023
Sou Extension 2 Granted
Sep 19, 2023
Sou Extension 2 Filed
Sep 19, 2023
Sou Teas Extension Received
Mar 14, 2023
Notice Of Approval Of Extension Request E-Mailed
Mar 10, 2023
Sou Extension 1 Granted
Mar 10, 2023
Sou Extension 1 Filed
Mar 10, 2023
Sou Teas Extension Received
Oct 18, 2022
Noa E-Mailed - Sou Required From Applicant
Sep 12, 2022
Applicant/Correspondence Changes (Non-Responsive) Entered
Sep 12, 2022
Teas Change Of Correspondence Received
Sep 12, 2022
Teas Change Of Owner Address Received
Aug 23, 2022
Official Gazette Publication Confirmation E-Mailed
Aug 23, 2022
Published For Opposition
Aug 3, 2022
Notification Of Notice Of Publication E-Mailed
Jul 19, 2022
Approved For Pub - Principal Register
Jul 19, 2022
Assigned To Examiner
Oct 18, 2021
Teas Amendment Entered Before Attorney Assigned
Oct 18, 2021
Teas Voluntary Amendment Received
Nov 4, 2021
Notice Of Design Search Code E-Mailed
Nov 3, 2021
New Application Office Supplied Data Entered
Oct 16, 2021
New Application Entered
Trademark Alertz updated from USPTO on 2030-01-24
